[en] BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome. PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis. Gender, age, presence of B symptoms, performance status (PS), histology, sites of tumor involvement, presence of effusion, clinical stage, age-adjusted International Prognostic Index, C-reactive protein (CRP), Hb, lactate deshydrogenase (LDH) and beta2-microglobulin were evaluated for their association with serum CA125 levels. The impact of CA125 levels and other features on overall (OS) and progression-free (PFS) survival was also assessed. RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD. Univariate analyses showed that CA125 levels correlated with poor PS, the presence of B symptoms, advanced clinical stage, abdominal, bone marrow or mediastinal involvement, presence of effusions, high aaIPI, low Hb levels and high CRP, LDH or beta2-microglobulin levels. In multivariate analysis, bone marrow involvement, the presence of effusions, and high aaIPI were all associated with high CA125 serum levels. In univariate analyses, OS and PFS were affected by age (PFS only), poor PS, B symptoms, advanced clinical stage, bone marrow or abdominal involvement (PFS only), high aaIPI, low Hb, high CRP or beta2-microglobulin levels. OS and PFS were not different in patients with normal or elevated CA125 levels. Multivariate analyses showed significantly inferior OS and PFS in patients with high beta2-microglobulin but no influence of CA125. CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD.
Disciplines :
Hematology
Author, co-author :
Bonnet, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fassotte, Marie-France ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Seidel, Laurence ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Luyckx, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Zacharos ID, Efstathiou SP, Petreli E, Georgiou G, Tsioulos DI, Mastorantonakis SE, Christakopoulou I, Roussou PP. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma. Eur J Haematol 2002;69:221-6.
Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A, Bellio L, Gargantini L, Morra E, Bernasconi C. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer 1998;82:576-82.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ HM, Kirgner I, Shaklai M. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1733-8.
Vlasveld LT, Ermens AAM, Sonnenberg AA, Pauwels P. Elevated serum Ca-125 concentrations due to expression by a diffuse large B-cell lymphoma. Ann Clin Biochem 2000;37:545-8.
Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist 2004;9:417-21.
Benboubker L, Valat C, Linassier C, Cartron G, Delain M, Bout M, Fetissof F, Lafranq T, Lamagnere JP, Colombat P. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels. Ann Oncol 2000;11:1485-91.
Ravoet C, Dargent JL, Le Moine F, Feremans W. CA-125 in primary mediastinal B-cell lymphoma with sclerosis. J Clin Oncol 1995;13:530-1.
Dilek I, Ayakta H, Demir C, Meral C, Ozturk M. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 2005;27:51-5.
Fehm T, Beck E, Valerius T, Gramatzki M, Jager W. CA 125 elevations in patients with malignant lymphomas. Tumour Biol 1998;19:283-9.
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
Schnitzer B. Classification of lymphomas. CRC Crit Rev Clin Lab Sci 1978;9:123-78.
Cox DR. Regression model and lifetables. J R Stat Soc 1972;34:187-220.
Pabst T, Ludwig C. CA-125: a tumor marker in non-Hodgkin's lymphomas? J Clin Oncol 1995;13:1827-8.
Morra E. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy. Int J Biol Markers 1999;14:149-53.
Kutluk T, Varan A, Erbas B, Buyukpamukcu M. Serum CA 125 levels in children with non-Hodgkin's lymphoma. Pediatr Hematol Oncol 1999;16:311-9.
Watanabe M, Kanda T, Takatama M, Iwai T, Naito I, Fukuda T, Hirai S. An autopsy case of malignant lymphoma with a high serum CA 125 level occurring only in the brain and pericardium. J Med 1996;27:221-7.
Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81.